Titan Pharmaceut Stock Price, News & Analysis

Titan Pharmaceuticals, Inc. (TTNP) is a development stage company that has focused on developing proprietary therapeutics utilizing its ProNeura® long-term, continuous drug delivery technology. According to multiple company disclosures, Titan’s ProNeura platform is designed to deliver medication continuously over extended periods, with the goal of maintaining consistent, around-the-clock blood levels of drugs for the treatment of chronic medical conditions.

The company’s stock historically traded on the Nasdaq Capital Market under the symbol TTNP. An SEC Form 25 filed by Nasdaq Stock Market LLC on October 2, 2025, identifies Titan Pharmaceuticals, Inc. as the issuer and confirms the removal of its common stock from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. This filing indicates that Titan’s common stock has been delisted from Nasdaq.

In its public communications, Titan has described itself as a development stage company working with the ProNeura technology to develop products for a number of chronic conditions where stable, continuous drug exposure may benefit patients and improve medical outcomes. Earlier descriptions of the business noted that Titan was developing proprietary therapeutics primarily for the treatment of serious medical disorders, and that its lead product was Probuphine®, an implant based on the ProNeura system for the treatment of opioid dependence. Titan later entered into an asset purchase agreement for the sale of certain ProNeura assets, including its portfolio of drug addiction products and other early development programs based on the ProNeura technology.

Under that asset purchase agreement with Fedson, Inc., Titan agreed to sell certain ProNeura assets, including its portfolio of drug addiction products (the Probuphine and Nalmefene implant programs) and other early development programs based on the ProNeura drug delivery technology. The company disclosed that it would receive upfront consideration and could potentially receive milestone payments and royalties on future net sales of those products, while Fedson would assume specified liabilities. In connection with this transaction, Titan stated that the sale would allow it to renew its focus on extracting value from its principal asset, TP-2021 for the treatment of pruritus.

Across several news releases, Titan has consistently highlighted the potential applications of the ProNeura platform in chronic conditions where maintaining consistent blood levels of medication may be beneficial. The company has also stated that, beginning in December 2021, it commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Subsequent corporate actions, including private placements of convertible preferred stock and a reverse stock split, were described in that context.

A significant corporate development for Titan was a business combination with TalenTec Sdn. Bhd. (formerly KE Sdn. Bhd.) through a reverse merger structure involving Black Titan Corporation, a Cayman Islands exempted company. Under a Merger and Contribution and Share Exchange Agreement dated August 19, 2024, TTNP Merger Sub, Inc., a wholly owned subsidiary of Black Titan, merged with and into Titan, with Titan continuing as the surviving corporation as a direct wholly owned subsidiary of Black Titan. An 8-K filed on October 1, 2025, reports that this business combination was completed on that date.

According to that 8-K, at the effective time of the merger, each share of Titan capital stock issued and outstanding immediately prior to the effective time was automatically converted into ordinary shares of Black Titan Corporation. In addition, under a related share exchange agreement, TalenTec shareholders exchanged their shares for ordinary shares of Black Titan. As a result, Titan became a wholly owned subsidiary of Black Titan, and it was anticipated that shares of TTNP common stock would cease trading on the Nasdaq Capital Market, with Black Titan ordinary shares expected to begin trading on Nasdaq.

Prior to completion of the business combination, Titan’s stockholders approved the merger and related proposals at a special meeting of stockholders held on August 26, 2025, as reported in another 8-K filing. The proposals included approval of the merger agreement and the issuance of Black Titan ordinary shares for purposes of Nasdaq Listing Rule 5635. The company also disclosed that completion of the merger remained subject to satisfaction of other closing conditions, including approval of the listing of Black Titan ordinary shares on Nasdaq.

In addition to the merger, Titan has reported several capital-raising transactions involving convertible preferred stock. For example, in September 2023 the company entered into a securities purchase agreement with The Sire Group Ltd. for Series AA Convertible Preferred Stock, and in April and June 2025 it entered into securities purchase agreements with Blue Harbour Asset Management L.L.C-FZ for Series B and Series C Convertible Preferred Stock, respectively. These preferred stock series included conversion features into common stock at specified conversion prices and beneficial ownership conversion limitations intended to comply with Nasdaq rules regarding ownership thresholds without shareholder approval.

Corporate governance and listing status have also been recurring themes in Titan’s disclosures. In late 2023, Titan announced a 1-for-20 reverse stock split of its common stock, with the stated purpose of adjusting the share price and share count while maintaining the same par value and rights of the common stock. In January 2024, Titan reported that Nasdaq had notified the company that it had regained compliance with the minimum bid price requirement and otherwise satisfied all applicable criteria for continued listing on the Nasdaq Capital Market. Later, in November 2024, Titan disclosed that it had received Nasdaq notices regarding delayed filing of a quarterly report and audit committee composition, and outlined the cure periods and steps it intended to take to address those matters.

Throughout these developments, Titan’s public statements have continued to describe it as a development stage company centered on proprietary therapeutics and the ProNeura long-term, continuous drug delivery technology, with strategic transactions—including asset sales, preferred stock financings, a reverse stock split, and the reverse merger with TalenTec via Black Titan—forming key elements of its corporate evolution. Following completion of the merger and the subsequent Form 25 delisting, TTNP functions primarily as the historical ticker and corporate entity that became a wholly owned subsidiary of Black Titan Corporation.

Business focus and technology

According to Titan’s own descriptions in multiple press releases, the company’s core business focus has been the development of proprietary therapeutics using its ProNeura drug delivery technology. ProNeura is described as a long-term, continuous drug delivery platform that can potentially be used to develop products for a number of chronic conditions where maintaining consistent, around-the-clock blood levels of medication may benefit patients and improve medical outcomes.

Historically, Titan’s portfolio included drug addiction products based on ProNeura, such as the Probuphine and Nalmefene implant programs, which were later sold to Fedson, Inc. under an asset purchase agreement. Titan has also publicly referenced TP-2021 for the treatment of pruritus as a principal asset following that sale. These disclosures underscore the company’s emphasis on long-acting implantable or continuous delivery treatments rather than short-acting or intermittent dosing approaches.

Corporate transactions and strategic alternatives

In December 2021, Titan stated that it had commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Subsequent events described in company news releases and SEC filings—including the sale of certain ProNeura assets, multiple private placements of convertible preferred stock, changes to the board of directors, a reverse stock split, and the reverse merger with TalenTec through Black Titan—fit within this framework of strategic actions.

The reverse merger structure, as outlined in the August 19, 2024 merger announcement and the October 1, 2025 8-K, involved Titan becoming a direct wholly owned subsidiary of Black Titan Corporation, with Titan stockholders and TalenTec shareholders receiving ordinary shares of Black Titan. This transaction effectively shifted the primary public listing from Titan’s TTNP common stock to Black Titan ordinary shares, with TTNP transitioning into a historical listing that has since been removed from Nasdaq under the Form 25.

Trading status and historical listing

Titan’s common stock was registered under Section 12(b) of the Securities Exchange Act and traded on the Nasdaq Capital Market under the symbol TTNP. The company has disclosed various interactions with Nasdaq, including regaining compliance with minimum bid price requirements in early 2024, receiving notices related to periodic reporting and audit committee composition in late 2024, and ultimately being the subject of a Form 25 filing on October 2, 2025 by Nasdaq to remove its common stock from listing and/or registration under Section 12(b).

In connection with the completed merger reported on October 1, 2025, Titan stated that it was anticipated that TTNP common stock would cease trading on Nasdaq and that Black Titan ordinary shares would begin trading on Nasdaq. The Form 25 subsequently filed by Nasdaq confirms the removal of Titan’s common stock from listing and/or registration on that exchange. As a result, TTNP should be viewed in the context of a former Nasdaq-listed security that now represents the historical equity of a company operating as a wholly owned subsidiary within a different public holding company structure.

Use of capital and financing structure

Titan’s SEC filings and press releases describe several private placements of convertible preferred stock as part of its financing activities. These include the issuance of Series AA Convertible Preferred Stock to The Sire Group Ltd., and Series B and Series C Convertible Preferred Stock to Blue Harbour Asset Management L.L.C-FZ. The certificates of designations for these preferred stock series establish conversion prices into common stock and include beneficial ownership conversion "blockers" that limit the holders’ ownership to the lower of a specified percentage under Nasdaq rules or 19.99% of Titan’s outstanding common stock, without prior shareholder approval.

These structures, as described in the relevant 8-K filings, reflect Titan’s approach to raising capital while managing ownership concentration and compliance with Nasdaq listing rules. The company also entered into registration rights agreements in connection with these placements, under which it agreed to provide certain registration rights upon the occurrence of specified events.

Position within the biopharmaceutical and drug delivery space

Based on the company’s own descriptions, Titan’s role within the broader biopharmaceutical and drug delivery landscape has been as a developer of long-acting, continuous drug delivery therapeutics using its proprietary ProNeura technology. The emphasis on chronic conditions, consistent blood levels of medication, and implant-based or continuous delivery approaches positions the company within the niche of long-term drug delivery platforms rather than traditional oral or injectable dosage forms administered on a frequent schedule.

Following the sale of certain ProNeura assets and the completion of the reverse merger with TalenTec via Black Titan, Titan’s historical business model and technology platform remain relevant for investors and researchers analyzing the evolution of long-acting drug delivery companies, even though TTNP common stock has been delisted and the corporate structure has changed.

TTNP as a historical ticker and corporate legacy

For users researching TTNP stock today, it is important to recognize that TTNP represents the former Nasdaq listing of Titan Pharmaceuticals, Inc. prior to its combination with TalenTec and its transition into a wholly owned subsidiary of Black Titan Corporation. The October 1, 2025 8-K and the October 2, 2025 Form 25 together document the completion of the merger and the removal of Titan’s common stock from Nasdaq listing and/or registration.

Historical information about Titan’s development activities, ProNeura technology, asset sale to Fedson, capital structure, reverse stock split, and strategic alternatives process provides context for understanding how the company reached this point. Investors and analysts examining TTNP as a historical symbol can use these disclosures to trace the company’s path from a development stage biopharmaceutical entity focused on long-term drug delivery to its role within a larger holding company structure following the reverse merger.